Cabozantinib

Drug Profile

Cabozantinib

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Dana-Farber Cancer Institute; Duke University Medical Center; Exelixis; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Swedish Orphan Biovitrum
  • Class Anilides; Antineoplastics; Cyclopropanes; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Thyroid cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Phase III Hepatocellular carcinoma
  • Phase II Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Fallopian tube cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Cancer; Colorectal cancer; Solid tumours
  • No development reported Astrocytoma; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 04 Mar 2017 Cabozantinib receives Orphan Drug status for Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in USA
  • 27 Feb 2017 Exelixis and Bristol-Myers Squibb plan a phase III trial in Renal cell carcinoma (First-line therapy)
  • 27 Feb 2017 Exelixis and Bristol-Myers Squibb plan clinical trials in Bladder cancer and Hepatocellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top